| Literature DB >> 31052556 |
Jiansen Hu1,2, Zheng Li3,4, Jieyu Gao5,6, Hongtao He7,8, Huanqin Dai9, Xuekui Xia10, Cuihua Liu11, Lixin Zhang12, Fuhang Song13.
Abstract
Six new diketopiperazines, (±)-7,8-epoxy-brevianamide Q ((±)-1), (±)-8-hydroxy-brevianamide R ((±)-2), and (±)-8-epihydroxy-brevianamide R ((±)-3), together with four known compounds, (±)-brevianamide R ((±)-4), versicolorin B (5) and averufin (6), were isolated from a marine-derived fungus strain Aspergillus versicolor MF180151, which was recovered from a sediment sample collected from the Bohai Sea, China. The chemical structures were established by 1D- and 2D-NMR spectra and HR-ESI-MS. 1 is the first sample of brevianamides with an epoxy moiety. Their bioactivities were evaluated against Candida albicans, Bacillus subtilis, Staphylococcus aureus, methicillin-resistant S. aureus, Pseudomonas aeruginosa, and Bacillus Calmette-Guérin. Compounds 1-4 showed no activities against the pathogens, and compounds 5 and 6 showed moderate activities against S. aureus and methicillin-resistant S. aureus.Entities:
Keywords: Aspergillus versicolor; antibacterial; diketopiperazine; marine-derived fungus
Mesh:
Substances:
Year: 2019 PMID: 31052556 PMCID: PMC6562876 DOI: 10.3390/md17050262
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1The structures of compounds 1–6.
Figure 2Morphology and neighbor-joining phylogenetic tree of strain MF180151. A: The morphology of the strain MF180151; B: The neighbor-joining phylogenetic tree of strain MF180151, numbers at nodes indicate levels of bootstrap support (%) based on a neighbor-joining analysis of 1,000 resampled datasets; only values >50% are given.
1H and 13C NMR data (600 MHz, DMSO-d6) for compounds 1–3.
| Position | 1 | 2 | 3 | |||
|---|---|---|---|---|---|---|
|
|
|
| ||||
| 1 | 163.1 | 160.9 | 162.9 | |||
| 2 | 9.37, s | 9.25, s | 9.35, s | |||
| 3 | 124.5 | 124.7 | 124.7 | |||
| 4 | 160.2 | 159.3 | 160.1 | |||
| 6a | 45.6 | 3.52, d (13.2) | 43.4 | 3.42, ddd (12.0, 10.2, 1.8) | 40.6 | 3.47, m |
| 6b | 3.94, overlap | 3.91, ddd (12.0, 8.4, 8.4) | ||||
| 7a | 51.1 | 3.95, overlap | 28.4 | 2.13, m | 27.6 | 2.12, m |
| 7b | 1.76, ddd (13.2, 8.4, 1.8) | 1.86, dq (12.0, 9.6) | ||||
| 8 | 57.4 | 3.93, overlap | 74.0 | 4.22 dd (4.8, 4.8) | 73.6 | 4.29, ddd (14.4, 6.0, 3.0) |
| 8-OH | 5.52, d (4.8) | 5.14, d (6.0) | ||||
| 9 | 86.0 | 94.5 | 87.1 | |||
| 9-OH | 7.54, s | |||||
| 9-OMe | 50.6 | 3.23, s | 51.8 | 3.42, s | ||
| 10 | 113.4 | 7.02, s | 112.0 | 7.04, s | 112.6 | 7.03, s |
| 11 | 104.0 | 103.3 | 103.7 | |||
| 12 | 126.2 | 126.2 | 126.2 | |||
| 13 | 119.7 | 7.32, d (7.8) | 118.6 | 7.14, d (7.8) | 119.0 | 7.22, d (7.8) |
| 14 | 119.3 | 7.00, dd (7.8, 7.8) | 119.5 | 7.02, dd (7.8, 7.8) | 119.4 | 7.02, dd (7.8, 7.8) |
| 15 | 120.7 | 7.08, dd (7.8, 7.8) | 120.8 | 7.10, dd (7.8, 7.8) | 120.8 | 7.09, dd (7.8, 7.8) |
| 16 | 111.4 | 7.41, d (7.8) | 111.7 | 7.43, d (7.8) | 111.6 | 7.42, d (7.8) |
| 17 | 135.1 | 135.2 | 135.1 | |||
| 18-NH | 11.06, s | 11.09, s | 11.09, s | |||
| 19 | 144.6 | 144.3 | 144.5 | |||
| 20 | 39.0 | 39.0 | 39.0 | |||
| 21 | 145.1 | 6.08, dd (17.4, 10.8) | 145.1 | 6.08, dd (17.4, 10.8) | 145.1 | 6.07, dd (17.4, 10.8) |
| 22a | 111.7 | 5.05, d (17.4) | 111.7 | 5.04, d (17.4) | 111.7 | 5.04, d (17.4) |
| 22b | 5.06, d (10.8) | 5.06, d (10.8) | 5.06, d (10.8) | |||
| 23 | 27.4 | 1.50, s | 27.4 | 1.49, s | 27.4 | 1.49, s |
| 24 | 27.8 | 1.45, s | 27.7 | 1.47, s | 27.7 | 1.45, s |
Figure 3COSY, Key HMBC and ROESY correlations of compounds 1–3.
Antimicrobial Activities of 1–6.
| Organism (strain) | Minimum Inhibitory Concentration (μg/mL) | ||||||
|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | Control | |
| Bacillus Calmette–Guérin (Pasteur 1173P2) | >100 | >100 | >100 | >100 | >100 | >100 | 0.05 a |
| >100 | >100 | >100 | >100 | 6.25 | 6.25 | 1 b | |
| methicillin-resistant | >100 | >100 | 100 | >100 | 12.5 | 25 | 1 b |
| >100 | >100 | >100 | >100 | >100 | >100 | 0.5 b | |
| >100 | >100 | >100 | >100 | >100 | >100 | 1 c | |
| >100 | >100 | >100 | >100 | 100 | >100 | 0.016 d | |
a Isoniazid; b Vancomycin; c Ciprofloxacin; d Ketoconazole.